Dosing9 min readUpdated 2026-04-10

    Ozempic Dosing Chart for Weight Loss: Week-by-Week Dose Guide

    See the Ozempic dosing chart for weight loss, including starting dose, escalation schedule, and what readers should understand about dose progression.

    Written by Trimi Medical Team. Medically reviewed by Dr. Sean Arora, MD. This article covers the Ozempic dosing chart in a weight-loss context, including starting dose, escalation, and how it relates to the broader semaglutide landscape.

    Quick links: Semaglutide treatment, Wegovy dosing, and side effects timeline.

    Standard Ozempic Dose Ladder

    Ozempic Weekly Dose Progression

    Weeks 1-4: 0.25 mg once weekly. Weeks 5-8: 0.5 mg once weekly. Then, depending on the treatment plan, dose adjustments may continue upward. The pace and endpoint depend on clinical context and provider guidance.

    Why Readers Search This in a Weight-Loss Context

    The "for weight loss" phrasing matters because searchers are not always thinking in strict label terms. They are often trying to compare Ozempic, Wegovy, and semaglutide generally. The strongest page should help readers understand the dose ladder while also clarifying the broader semaglutide context.

    Why the Dose Increases Gradually

    Start low to help the body adjust to semaglutide

    Increase gradually because GI side effects are most common early

    Escalation is about tolerability, not about reaching the highest dose fastest

    Timing matters: rushing can make side effects worse than necessary

    For side-effect patterns at each stage, see our semaglutide side effects week by week guide. For expected outcomes, see semaglutide results after 3 months.

    What Readers Should Keep in Mind

    Why is the dose changing at this point in your treatment?

    Are you tolerating the current dose well before moving up?

    Are you comparing Ozempic with Wegovy correctly for your goals?

    What should you ask if side effects make escalation difficult?

    For the complete semaglutide picture, explore what happens when you stop semaglutide and semaglutide cost with insurance.

    Frequently Asked Questions

    What is the starting dose for Ozempic?

    Ozempic is typically started at 0.25 mg once weekly. This low starting dose helps the body adjust to semaglutide and reduces the likelihood of severe gastrointestinal side effects during the initial treatment period.

    What does the Ozempic dose escalation look like?

    The usual weekly progression starts at 0.25 mg for weeks 1 to 4, then increases to 0.5 mg for weeks 5 to 8. Depending on the treatment plan, dose adjustments may continue upward from there. The exact progression depends on clinical context and provider guidance.

    Why do people search for Ozempic dosing in a weight-loss context?

    Readers often search Ozempic dosing for weight loss because semaglutide is widely associated with both diabetes care and weight-management discussions. The for weight loss phrasing matters because searchers are not always thinking in strict label terms and may be comparing Ozempic, Wegovy, and semaglutide generally.

    Why does Ozempic dose increase gradually?

    As with other semaglutide products, gradual escalation is mainly about tolerability. Gastrointestinal side effects often show up early, especially nausea, vomiting, diarrhea, constipation, and appetite shifts. The dosing chart is part of side-effect management as much as it is part of the treatment plan.

    How does Ozempic dosing compare to Wegovy dosing?

    Both Ozempic and Wegovy use semaglutide, but they have different dose ranges and approved uses. Wegovy was specifically developed and dosed for weight management, while Ozempic is primarily indicated for type 2 diabetes. The escalation principles are similar but the specific dose levels differ.

    Should I treat Ozempic dose progression like a race?

    No. The strongest version of the dosing chart should explain why the dose starts low, why escalation is gradual, why you should not rush through dose increases, and why timing matters if symptoms become harder to tolerate. Patience during titration leads to better long-term tolerance.

    What should I ask my clinician about Ozempic dosing?

    Ask why the dose is changing at the current point, whether you are tolerating the current dose well, how Ozempic compares with Wegovy for your goals, and what to do if side effects make escalation difficult. These questions help you engage actively in your treatment plan.

    Sources & References

    1. Ozempic prescribing information. FDA.
    2. Wegovy prescribing information. FDA.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, adjusting, or discontinuing any medication. Individual results vary. Dose adjustments should only be made under medical supervision.

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx, Texas pharmacy license #35264, and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo., STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm., STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes., SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 10, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    - Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    - Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    Can Weight Loss Start After the Second Dose. Read the full clinician-reviewed Trimi guide, practical guidance plus Trimi's $99/mo compounded GLP-1 alternative for context.

    Start your GLP-1 journey, from $99/mo

    Get Started